Cite
HARVARD Citation
Taylor, P. et al. (2022). Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Annals of the rheumatic diseases. 81 (3), pp. 335-343. [Online].